^
    3d
    A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=47, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Oct 2026 --> Jul 2026
    Enrollment open • Trial initiation date
    |
    CD4 (CD4 Molecule)
    |
    Inqovi (decitabine/cedazuridine) • Neupogen (filgrastim)
    3d
    Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors (clinicaltrials.gov)
    P2, N=132, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Neupogen (filgrastim)
    5d
    GRACE: GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study (clinicaltrials.gov)
    P4, N=75, Completed, Nationwide Children's Hospital | Active, not recruiting --> Completed | N=120 --> 75
    Trial completion • Enrollment change
    |
    Leukine (sargramostim)
    5d
    NCI-2011-00344: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=8, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Neupogen (filgrastim) • plerixafor
    10d
    Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma (clinicaltrials.gov)
    P3, N=479, Completed, Children's Oncology Group | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • mesna • Neupogen (filgrastim)
    12d
    Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=245, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Yervoy (ipilimumab) • Leukine (sargramostim)
    13d
    Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS) (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Northwell Health | Initiation date: Oct 2025 --> Jun 2026
    Trial initiation date
    |
    Neupogen (filgrastim) • plerixafor
    17d
    Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    |
    Leukine (sargramostim) • Panvac-VF (falimarev/inalimarev)
    18d
    A Double-Blind, Randomized Controlled, Multicenter Study on Granulocyte Colony-Stimulating Factor for the Treatment of Unexplained Recurrent Spontaneous Abortion (ChiCTR2600118421)
    P=N/A, N=200, Women's Hospital School of Medicine Zhejiang University; Women's Hospital School of Medicine Zhejiang University
    New trial
    |
    Neupogen (filgrastim)
    25d
    Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: May 2026 --> Jul 2026
    Trial initiation date
    |
    cyclophosphamide • topotecan • Qarziba (dinutuximab beta) • iberdomide (CC-220) • Unituxin (dinutuximab) • Leukine (sargramostim)
    1m
    Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines. (PubMed, Pharmaceuticals (Basel))
    We discussed major OV platforms with respect to payload capacity, expression control, manufacturability, and clinical track records, including lessons learned from approved or late-stage OVs such as talimogene laherparepvec (T-VEC) and teserpaturev/G47Δ. Finally, we propose a pragmatic clinical workflow for rapid personalization to maximize therapeutic index. Tightly integrating neoantigen science with immunovirotherapy, including recent 2025 preclinical advances like oncolytic adenovirus neoantigen delivery sensitizing low-TMB tumors to PD-1 blockade, could enable next-generation personalized cancer vaccines capable of converting "cold" tumors into responsive, systemically controlled disease.
    Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-L
    |
    Imlygic (talimogene laherparepvec) • Delytact (teserpaturev)
    2ms
    Efficacy of the Granulocyte Colony-Stimulating Factor in Sepsis-Associated Immunosuppression: An Open-Label Randomized Controlled Trial. (PubMed, Cureus)
    Filgrastim (G-CSF) use in immunocompetent children with sepsis-induced MOFS is safe, and a 2-dose of filgrastim (G-CSF) for three days has poor efficacy in the reduction of mortality and did not show significant change in frequency of HAI, TNF-α levels, and pSOFA scores.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • FASLG (Fas ligand) • FAS (Fas cell surface death receptor)
    |
    Neupogen (filgrastim)